NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Chronic Conditions (UK). Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians (UK); 2003. (NICE Clinical Guidelines, No. 5.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Chronic Heart Failure

Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care.

Show details

References

1.
Petersen S, Rayner M, Wolstenholme J. Coronary heart disease statistics: heart failure supplement. London: British Heart Foundation; 2002.
2.
Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. European Heart Journal. 1999;20:421–8. [PubMed: 10213345]
3.
Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001;358:439–44. [PubMed: 11513906]
4.
Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, et al. Coronary artery disease as the cause of incident heart failure in the population. European Heart Journal. 2001;22:228–36. [PubMed: 11161934]
5.
Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83:505–10. [PMC free article: PMC1760808] [PubMed: 10768897]
6.
Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales 1950–1999. London: The Stationery Office; 2001.
7.
Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation. 2002;105:2861–6. [PubMed: 12070114]
8.
Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. European Journal of Heart Failure. 2001;3:283–91. [PubMed: 11377998]
9.
Leidy NK, Rentz AM, Zyczynski TM. Evaluating health-related quality-of-life outcomes in patients with congestive heart failure. A review of recent randomised controlled trials. Pharmacoeconomics. 1999;15:19–46. [PubMed: 10345157]
10.
Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technology Assessment. 2001;5:1–69. [PubMed: 11427188]
11.
National Institute for Clinical Excellence. Information for National Collaborating Centres and Guideline Development Groups. 2001. (The Guideline Development Process series).
12.
Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technology Assessment. 1998;2 [PubMed: 9561895]
13.
Fitch K, Bernstein S, Aguilar M. The RAND/UCLA appropriateness method: users manual. 2001.
14.
Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the chest radiograph diagnose left ventricular dysfunction? Journal of General Internal Medicine. 1996;11:625–34. [PubMed: 8945695]
15.
Ikram H. Identifying the patient with heart failure. Journal of International Medical Research. 1995;23:139–53. [PubMed: 7649338]
16.
Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal. 2001;22:1527–60. [PubMed: 11492984]
17.
Geltman EM. Mild heart failure: diagnosis and treatment. American Heart Journal. 1989;118:1277–91. [PubMed: 2686381]
18.
Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? Quarterly Journal of Medicine. 1997;90:335–9. [PubMed: 9205668]
19.
Johnstone DE, Abdulla A, Arnold JM, Bernstein V, Bourassa M, Brophy J, et al. Diagnosis and management of heart failure. Canadian Cardiovascular Society. Canadian Journal of Cardiology. 1994;10:613–31. [PubMed: 8044722]
20.
Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. American Family Physician. 2000;61:1319–28. [PubMed: 10735340]
21.
Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? Journal of the American Medical Association. 1997;277:1712–9. [PubMed: 9169900]
22.
Chakko S, Woska D, Martinez H, de M, Futterman L, Kessler KM, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. American Journal of Medicine. 1991;90:353–9. [PubMed: 1825901]
23.
Khunti K, Baker R, Grimshaw G. Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations. British Journal of General Practice. 2000;50:50–4. [PMC free article: PMC1313613] [PubMed: 10695070]
24.
Ghali JK, Kadakia S, Cooper RS, Liao YL. Bedside diagnosis of preserved versus impaired left ventricular systolic function in heart failure. American Journal of Cardiology. 1991;67:1002–6. [PubMed: 2018002]
25.
Davies LC, Francis DP, Piepoli M, Scott AC, Ponikowski P, Coats AJ. Chronic heart failure in the elderly: value of cardiopulmonary exercise testing in risk stratification. Heart. 2000;83:147–51. [PMC free article: PMC1729303] [PubMed: 10648485]
26.
Houghton AR, Sparrow NJ, Toms E, Cowley AJ. Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography? International Journal of Cardiology. 1997;62:31–6. [PubMed: 9363500]
27.
Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. European Heart Journal. 1991;12:315–21. [PubMed: 2040313]
28.
Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–53. [PubMed: 9365448]
29.
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New England Journal of Medicine. 2002;347:161–7. [PubMed: 12124404]
30.
Selvais PL, Donckier JE, Robert A, Laloux O, van L, Ahn S, Van Linden F, et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. European Journal of Clinical Investigation. 1998;28:636–42. [PubMed: 9767358]
31.
Yamamoto K, Burnett JCJ, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988–94. [PubMed: 8952587]
32.
Davis KM, Fish LC, Elahi D, Clark BA, Minaker KL. Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. Journal of the American Medical Association. 1992;267:2625–9. [PubMed: 1533427]
33.
Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clinical Endocrinology. 1997;47:287–96. [PubMed: 9373449]
34.
Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. British Medical Journal. 2000;320:906–8. [PMC free article: PMC27331] [PubMed: 10741999]
35.
Arnold JM, Cheung P, Burton GL. Continuous wave Doppler measurements of aortic bloodflow during exercise in patients with chronic heart failure. Canadian Journal of Cardiology. 1994;10:185–92. [PubMed: 8143219]
36.
Senni M, Rodeheffer RJ, Tribouilloy CM, Evans JM, Jacobsen SJ, Bailey KR, et al. Use of echo-cardiography in the management of congestive heart failure in the community. Journal of the American College of Cardiology. 1999;33:164–70. [PubMed: 9935024]
37.
Roelandt J, Lubsen J. Usefulness of quantitative echocardiography in congestive heart failure. European Heart Journal. 1983;4(Suppl A):95–9. [PubMed: 6840125]
38.
Hanrath P, Schluter M. Is echocardiography a reliable tool? European Heart Journal. 1983;4:89–94. [PubMed: 6220902]
39.
Semelka RC, Tomei E, Wagner S, Mayo J, Caputo G, O’Sullivan M, et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. American Heart Journal. 1990;119:1367–73. [PubMed: 2141222]
40.
Buser PT, Auffermann W, Holt WW, Wagner S, Kircher B, Wolfe C, et al. Noninvasive evaluation of global left ventricular function with use of cine nuclear magnetic resonance. Journal of the American College of Cardiology. 1989;13:1294–300. [PubMed: 2703612]
41.
Wagner S, Buser P, Auffermann W, Holt WW, Wolfe CL, Higgins CB. Cine magnetic resonance imaging: tomographic analysis of left ventricular function. Cardiology Clinics. 1989;7:651–9. [PubMed: 2670231]
42.
Massie B. Updated diagnosis and management of congestive heart failure. Geriatrics. 1986;41:30–5. [PubMed: 3949161]
43.
Tresch DD. Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clinics in Geriatric Medicine. 2000;16:445–56. [PubMed: 10918641]
44.
Haas GJ, Leier CV. Invasive cardiovascular testing in chronic congestive heart failure. Critical Care Medicine. 1990;18:S1–S4. [PubMed: 2403509]
45.
McKelvie RS, Teo KK, McCartney N, Humen D, Montague T, Yusuf S. Effects of exercise training in patients with congestive heart failure: a critical review. Journal of the American College of Cardiology. 1995;25:789–96. [PubMed: 7860930]
46.
Pu CT, Johnson MT, Forman DE, Hausdorff JM, Roubenoff R, Foldvari M, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. Journal of Applied Physiology. 2001;90:2341–50. [PubMed: 11356801]
47.
Lloyd-Williams F, Mair FS, Leitner M. Exercise training and heart failure: a systematic review of current evidence. British Journal of General Practice. 2002;52:47–55. [PMC free article: PMC1314201] [PubMed: 11791816]
48.
Bernardi L. Modifying breathing patterns in chronic heart failure. European Heart Journal. 1999;20:83–4. [PubMed: 10099900]
49.
Frye BA. Review of the World Health Organization’s report on disability prevention and rehabilitation. Rehabilitation Nursing. 1993;18:43–4. [PubMed: 8430265]
50.
NHS Centre for Reviews and Dissemination. Cardiac rehabilitation. Effective health care. 1998;4(4)
51.
Dracup K, Baker DW, Dunbar SB, Dacey RA, Brooks NH, Johnson JC, et al. Management of heart failure. II. Counseling, education, and lifestyle modifications. Journal of the American Medical Association. 1994;272:1442–6. [PubMed: 7933427]
52.
Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Systematic Review. 2000:CD001292. [PubMed: 10796638]
53.
Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Systematic Review. 2000:CD001118. [PubMed: 10796601]
54.
Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest. 2002;121:1638–50. [PubMed: 12006456]
55.
Friedman HS. Cardiovascular effects of alcohol with particular reference to the heart. Alcohol. 1984;1:333–9. [PubMed: 6399213]
56.
Kostis JB, Rosen RC, Cosgrove NM, Shindler DM, Wilson AC. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. Chest. 1994;106:996–1001. [PubMed: 7924541]
57.
Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. International Journal of Cardiology. 1995;49:191–9. [PubMed: 7649665]
58.
Morelli V, Zoorob RJ. Alternative therapies: Part II. Congestive heart failure and hypercholesterolemia. American Family Physician. 2000;62:1325–30. [PubMed: 11011861]
59.
Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. Journal of the American College of Cardiology. 1999;33:1549–52. [PubMed: 10334422]
60.
Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator. 1993;71:S134–S136. [PubMed: 8241697]
61.
Hofman BC, Rehnqvist N, Swedberg K, Wiklund I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. Journal of Cardiac Failure. 1995;1:101–7. [PubMed: 9420639]
62.
Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Archives of Internal Medicine. 1984;144:1745–8. [PubMed: 6476990]
63.
Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation. 1999;99:168–77. [PubMed: 9884398]
64.
British Heart Foundation. Coronary heart disease and air travel. 2002.
65.
Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. International Journal of Cardiology. 2002;82:149–58. [PubMed: 11853901]
66.
Braunschweig F, Linde C, Eriksson MJ, Hofman-Bang C, Ryden L. Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. European Heart Journal. 2002;23:59–69. [PubMed: 11741363]
67.
Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet. 1986;2:770–2. [PubMed: 2876233]
68.
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary of a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996–3007. [PubMed: 11739319]
69.
Neal B, MacMahon S, Chapman N, Blood P. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356:1955–64. [PubMed: 11130523]
70.
Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575–81. [PubMed: 10821360]
71.
ACE inhibitors in the primary care management of adults with symptomatic heart failure, North of England Evidence Based Guideline Development Project. Centre for Health Services Research, University of Newcastle Upon Tyne; 2001.
72.
Lubsen J, Chadha DR, Yotof YT, Swedberg K. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. American Journal of Cardiology. 1996;77:1191–6. [PubMed: 8651094]
73.
Mancini GB. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clinical & Investigative Medicine – Médecine Clinique et Experimentale. 2000;23:144–61. [PubMed: 10852664]
74.
Beller B, Bulle T, Bourge RC, Colfer H, Fowles RE, Giles TD, et al. Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group. Journal of Clinical Pharmacology. 1995;35:673–80. [PubMed: 7560247]
75.
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–8. [PubMed: 10587334]
76.
Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. Journal of the American College of Cardiology. 2002;39:70–8. [PubMed: 11755289]
77.
Bouzamondo A, Hulot JS, Sanchez P, Cucherat M, Lechat P. Beta-blocker treatment in heart failure. Fundamental & Clinical Pharmacology. 2001;15:95–109. [PubMed: 11468019]
78.
Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Annals of Internal Medicine. 2001;134:550–60. [PubMed: 11281737]
79.
Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. European Journal of Heart Failure. 2001;3:351–7. [PubMed: 11378007]
80.
Whorlow SL, Krum H. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. American Journal of Cardiology. 2000;86:886–9. [PubMed: 11024409]
81.
Bonet S, Agusti A, Arnau JM, Vidal X, Diogene E, Galve E, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials. Archives of Internal Medicine. 2000;160:621–7. [PubMed: 10724047]
82.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine. 2001;344:1651–8. [PubMed: 11386263]
83.
Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. American Heart Journal. 2001;141:899–907. [PubMed: 11376302]
84.
The Beta Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine. 2001;344:1659–67. [PubMed: 11386264]
85.
Poole-Wilson PA, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Metra M, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. European Journal of Heart Failure. 2002;4:321–9. [PubMed: 12034158]
86.
The Cardiac, Insufficiency Bisoprolol, Study II. (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13. [PubMed: 10023943]
87.
Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. Clinical Cardiology. 1999;22:V30–V35. [PubMed: 10526701]
88.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999;353:2001–7. [PubMed: 10376614]
89.
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. Journal of the American Medical Association. 2000;283:1295–302. [PubMed: 10714728]
90.
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994;90:1765–73. [PubMed: 7923660]
91.
Spertus JA, Tooley J, Jones P, Poston C, Mahoney E, Deedwania P, et al. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone’s neuroHormonal Efficacy and SUrvival Study) American Heart Journal. 2002;143:636–42. [PubMed: 11923800]
92.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine. 1999;341:709–17. [PubMed: 10471456]
93.
Ramires FJ, Mansur A, Coelho O, Maranhao M, Gruppi CJ, Mady C, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardio-myopathy. American Journal of Cardiology. 2000;85:1207–11. [PubMed: 10802002]
94.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine. 2003;348:1309–21. [PubMed: 12668699]
95.
van Veldhuisen DJ, Man-in-’t-Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT) Journal of the American College of Cardiology. 1993;22:1564–73. [PubMed: 7901256]
96.
Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. Journal of the American College of Cardiology. 1993;22:955–62. [PubMed: 8409069]
97.
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. New England Journal of Medicine. 1997;336:525–33. [PubMed: 9036306]
98.
McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. European Journal of Heart Failure. 2001;3:495–502. [PubMed: 11511437]
99.
Ward RE, Gheorghiade M, Young JB, Uretsky B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. Journal of the American College of Cardiology. 1995;26:93–101. [PubMed: 7797781]
100.
Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. Journal of the American College of Cardiology. 2002;39:463–70. [PubMed: 11823085]
101.
Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. American Heart Journal. 2000;139:609–17. [PubMed: 10740141]
102.
Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. American Journal of Cardiology. 2000;85:187–92. [PubMed: 10955375]
103.
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine. 2001;345:1667–75. [PubMed: 11759645]
104.
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–7. [PubMed: 10821361]
105.
Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al. Candesartan in heart failure –assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. Journal of Cardiac Failure. 1999;5:276–82. [PubMed: 10496201]
106.
Dasbach EJ, Rich MW, Segal R, Gerth WC, Carides GW, Cook JR, et al. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology. 1999;91:189–94. [PubMed: 10516413]
107.
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997;350:1417–24. [PubMed: 9371164]
108.
Piepoli M, Villani GQ, Ponikowski P, Wright A, Flather MD, Coats AJ. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. International Journal of Cardiology. 1998;66:1–10. [PubMed: 9781781]
109.
Cleland JG, Dargie HJ. Ventricular arrhythmias during exercise in patients with heart failure: the effect of amiodarone. European Heart Journal. 1987;8(Suppl D):65–9. [PubMed: 3678263]
110.
Kober L, Bloch T, Moller M, Torp-Pedersen C, Carlsen J, Sandoe E, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 2000;356:2052–8. [PubMed: 11145491]
111.
Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine. 1999;341:857–65. [PubMed: 10486417]
112.
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Archives of Internal Medicine. 1994;154:1449–57. [PubMed: 8018000]
113.
Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database Systematic Review. 2001:CD003333. [PubMed: 11687189]
114.
Fitzmaurice DA, Machin SJ. Recommendations for patients undertaking self management of oral anticoagulation. British Medical Journal. 2001;323:985–9. [PMC free article: PMC1121512] [PubMed: 11679391]
115.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal. 2002;324:71–86. [PMC free article: PMC64503] [PubMed: 11786451]
116.
Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart. 1998;80:S1–S29. [PMC free article: PMC1766497] [PubMed: 10193438]
117.
Olson KL. Combined aspirin/ACE inhibitor treatment for CHF. Annals of Pharmacotherapy. 2001;35:1653–8. [PubMed: 11793637]
118.
Cleland JG. Is aspirin ‘the weakest link’ in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Progress in Cardiovascular Diseases. 2002;44:275–92. [PubMed: 12007083]
119.
Takkouche B, Etminan M, Caamano F, Rochon PA. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Drug Safety. 2002;25:373–8. [PubMed: 12020174]
120.
Lapane KL, Hume AL, Barbour MM, Lipsitz LA. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? Journal of the American Geriatrics Society. 2002;50:1198–204. [PubMed: 12133013]
121.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine. 1991;325:293–302. [PubMed: 2057034]
122.
Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–9. [PubMed: 7968073]
123.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine. 1996;335:1001–9. [PubMed: 8801446]
124.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine. 1998;339:1349–57. [PubMed: 9841303]
125.
Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current Medical Research and Opinion. 2002;18:220–8. [PubMed: 12201623]
126.
Kjekshus J, Pedersen T-R, Olsson A-G, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. Journal of Cardiac Failure. 1997;3:249–54. [PubMed: 9547437]
127.
Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? Journal of the American College of Cardiology. 2002;39:1567–73. [PubMed: 12020481]
128.
Pickin DM, Payne JN, Haq I. Guidance Notes for Purchasers. Trent Institute for Health Services Research; 1996. Working Group on Acute Purchasing: Statin therapy/HMG Co-A reductase inhibitor treatment int he prevention of coronary heart disease. 96/04.
129.
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. New England Journal of Medicine. 1986;314:1547–52. [PubMed: 3520315]
130.
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine. 1991;325:303–10. [PubMed: 2057035]
131.
Fonarow GC, Chelimsky FC, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. Journal of the American College of Cardiology. 1992;19:842–50. [PubMed: 1545080]
132.
Ghose JC, Chakraborty S, Mondal M, Bhandari B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Journal of the Association of Physicians of India. 1993;41:269–71. [PubMed: 8300456]
133.
Lin M, Chiang HT, Chen CY, Chiang BN. Comparison of enalapril and conventional vasodilator therapy in patients with chronic congestive heart failure. Journal of the Formosan Medical Association. 1991;90:452–9. [PubMed: 1680982]
134.
Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971–7. [PubMed: 9100622]
135.
Rector TS, Johnson G, Dunkman WB, Daniels G, Farrell L, Henrick A, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI71–77. [PubMed: 8500243]
136.
Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. Journal of the American College of Cardiology. 1993;22:65–72. [PubMed: 8509565]
137.
Parker JO. The effects of oral ibopamine in patients with mild heart failure – a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. International Journal of Cardiology. 1993;40:221–7. [PubMed: 8225657]
138.
Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. American Heart Journal. 1999;138:247–53. [PubMed: 10426835]
139.
Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. Journal of the American College of Cardiology. 2000;36:501–8. [PubMed: 10933364]
140.
Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Journal of the American Medical Association. 2002;287:1541–7. [PubMed: 11911756]
141.
Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. New England Journal of Medicine. 1998;339:1810–6. [PubMed: 9854116]
142.
Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich NJ, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223–31. [PMC free article: PMC484511] [PubMed: 8868980]
143.
Henriksson L, Sundin A, Smedby O, Albrektsson P. Assessment of congestive heart failure in chest radiographs. Observer performance with two common film-screen systems. Acta Radiologica. 1990;31:469–71. [PubMed: 2261292]
144.
Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure – a meta-regression analysis. European Journal of Heart Failure. 2002;4:515–29. [PubMed: 12167393]
145.
O’Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. American Journal of Cardiology. 1998;82:881–7. [PubMed: 9781971]
146.
Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96:856–63. [PubMed: 9264493]
147.
Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. New England Journal of Medicine. 1996;335:1107–14. [PubMed: 8813041]
148.
van der Vring JA, Bernink PJ, van der Wall EE, van Velhuisen DJ, Braun S, Kobrin I. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure. Clinical Therapeutics. 1996;18:1191–206. [PubMed: 9001836]
149.
Walsh JT, Andrews R, Curtis S, Evans A, Cowley AJ. Effects of amlodipine in patients with chronic heart failure. American Heart Journal. 1997;134:872–8. [PubMed: 9398099]
150.
Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. Journal of the American College of Cardiology. 2002;39:798–803. [PubMed: 11869844]
151.
Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. American Journal of Cardiology. 2001;88:35–9. [PubMed: 11423055]
152.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. Journal of the American Medical Association. 2002;287:1531–40. [PubMed: 11911755]
153.
Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. Journal of the American College of Cardiology. 2000;36:1903–12. [PubMed: 11092663]
154.
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202. [PubMed: 12133653]
155.
Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222–7. [PubMed: 11056096]
156.
Waldo AL, Camm AJ, DeRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7–12. [PubMed: 8691967]
157.
Sueta CA, Gheorghiade M, Adams KFJ, Bourge RC, Murali S, Uretsky BF, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. American Journal of Cardiology. 1995;75:34A–43A. [PubMed: 7840053]
158.
Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) American Heart Journal. 1997;134:44–54. [PubMed: 9266782]
159.
Keith ME, Jeejeebhoy KN, Langer A, Kurian R, Barr A, O’Kelly B, et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. American Journal of Clinical Nutrition. 2001;73:219–24. [PubMed: 11157316]
160.
Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233–7. [PubMed: 9643742]
161.
Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. American Heart Journal. 2000;139:S120–S123. [PubMed: 10650325]
162.
Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103:1083–8. [PubMed: 11222470]
163.
Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2003;104:39–45. [PubMed: 11435335]
164.
Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. Journal of the American College of Cardiology. 2001;37:1775–80. [PubMed: 11401110]
165.
Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalisations. Journal of the American College of Cardiology. 2000;35:1737–44. [PubMed: 10841219]
166.
Jaarsma T, Dracup K. Determinants of health-care utilisation by patients with chronic heart failure. In: Stewart S, Blue L, editors. Improving outcomes in chronic heart failure: a practical guide to specialist nurse intervention. London: BMJ Books; 2001.
167.
Opasich C, Febo O, Riccardi PG, Traversi E, Forni G, Pinna G, et al. Concomitant factors of decompensation in chronic heart failure. American Journal of Cardiology. 1996;78:354–7. [PubMed: 8759821]
168.
Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Library. 2002 [PubMed: 12076376]
169.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics. 2001;23:1296–310. [PubMed: 11558866]
170.
Newell SA, Bowman JA, Cockburn JD. A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment-keeping in the treatment of cardiovascular disease. Preventive Medicine. 1999;29:535–48. [PubMed: 10600435]
171.
Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. European Heart Journal. 2000;21:614–32. [PubMed: 10731399]
172.
De Bock V, Mets T, Romagnoli M, Derde MP. Captopril treatment of chronic heart failure in the very old. Journal of Gerontology. 1994;49:M148–M152. [PubMed: 8169337]
173.
Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drugs & Aging. 2000;16:227–50. [PubMed: 10803861]
174.
Luparini RL, Celli V, Piccirillo G. Carvedilol in elderly patients with chronic heart failure, a twelve week randomised, placebo controlled trial. Archives of Gerontology and Geriatrics. 2000;29:275–82. [PubMed: 15374060]
175.
Hood WB, Dans A, Guyatt GH, Jaeschke R, McMurray JV. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database Systematic Review. 2001 [PubMed: 11687032]
176.
Rathore SS. Sex-based differences in the effect of digoxin for the treatment of heart failure. New England Journal of Medicine. 2002;347:1403–11. [PubMed: 12409542]
177.
Brown CS, Bertolet BD. Peripartum cardiomyopathy: a comprehensive review. American Journal of Obstetrics and Gynecology. 1998;178:409–14. [PubMed: 9500508]
178.
El Banayosy A, Fey O, Sarnowski P, Arusoglu L, Boethig D, Milting H, et al. Midterm follow-up of patients discharged from hospital under left ventricular assistance. Journal of Heart & Lung Transplantation. 2001;20:53–8. [PubMed: 11166612]
179.
Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. Journal of the American Medical Association. 1994;272:1528–34. [PubMed: 7966846]
180.
Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68:939–50. [PubMed: 6137292]
181.
Sculpher MJ, Petticrew M, Kelland JL, Elliot RA, Holdright DR, Buxton MJ. Resource allocation for chronic stable angina: a systematic review of the effectiveness, costs and cost-effectiveness of alternative interventions. Health Technology Assessment. 1998;2(10) [PubMed: 9812243]
182.
Stevenson LW. Selection and management of candidates for heart transplantation. Current Opinion in Cardiology. 1996;11:166–73. [PubMed: 8736688]
183.
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. New England Journal of Medicine. 2001;345:1435–43. [PubMed: 11794191]
184.
Holman WL, Skinner JL, Waites KB, Benza RL, McGiffin DC, Kirklin JK. Infection during circulatory support with ventricular assist devices. Annals of Thoracic Surgery. 1999;68:711–6. [PubMed: 10475476]
185.
Gracin N, Johnson MR, Spokas D, Allen J, Bartlett L, Piccione W, et al. The use of APACHE II scores to select candidates for left ventricular assist device placement. Acute Physiology and Chronic Health Evaluation. Journal of Heart & Lung Transplantation. 1998;17:1017–23. [PubMed: 9811411]
186.
Mancini DM, Beniaminovitz A, Levin H, Catanese K, Flannery M, DiTullio M, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation. 1998;98:2383–9. [PubMed: 9832482]
187.
Stellbrink C, Auricchio A, Diem B, Breithardt O-A, Kloss M, Schondube FA, et al. Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. American Journal of Cardiology. 1999;83:143D–50D. [PubMed: 10089857]
188.
Linde C, Leclercq C, Rex S. Long term benefits of biventricular pacing in congestive heart failure: results form the MUltisite STimulation in cardiomyopathy (MUSTIC) study. Journal of the American College of Cardiology. 2002;40:111–8. [PubMed: 12103264]
189.
Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. New England Journal of Medicine. 2001;344:873–80. [PubMed: 11259720]
190.
Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. New England Journal of Medicine. 2002;346:1845–53. [PubMed: 12063368]
191.
Lozano I, Bocchiardo M, Achtelik M, Gaita F, Trappe HJ, Daoud E, et al. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias. Pacing & Clinical Electrophysiology. 2000;23:t-2. [PubMed: 11139906]
192.
Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. Journal of Cardiac Failure. 2000;6:276–85. [PubMed: 10997756]
193.
Parkes J, Bryant J, Milne R. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review. Health Technology Assessment. 2000;4(1) [PubMed: 11086270]
194.
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. New England Journal of Medicine. 1997;337:1576–83. [PubMed: 9411221]
195.
Athanasuleas CL, Stanley AW, Buckberg GD, Dor V, Di Donato M, Siler W. Surgical anterior ventricular endocardial restoration (SAVER) for dilated ischemic cardiomyopathy. Seminars in Thoracic and Cardiovascular Surgery. 2001;13:448–58. [PubMed: 11807740]
196.
Acker MA. Dynamic cardiomyoplasty: at the crossroads. Annals of Thoracic Surgery. 1999;68:750–5. [PubMed: 10475482]
197.
Ingbir M, Freimark D, Motro M, Adler Y. The incidence, pathophysiology, treatment and prognosis of Cheyne-Stokes breathing disorder in patients with congestive heart failure. Herz. 2002;27:107–12. [PubMed: 12025457]
198.
Obenza NE, Liu LC, Coulter TD, Gassler JP, Dinner DS, Mills RM. Heart failure and sleep-related breathing disorders. Cardiology in Review. 2000;8:191–201. [PubMed: 11174895]
199.
Andreas S, Clemens C, Sandholzer H, Figulla HR, Kreuzer H. Improvement of exercise capacity with treatment of Cheyne-Stokes respiration in patients with congestive heart failure. Journal of the American College of Cardiology. 1996;27:1486–90. [PubMed: 8626963]
200.
Wedzicha JA. Domiciliary oxygen therapy services: clinical guidelines and advice for prescribers, Summary of a report of the Royal College of Physicians. London: RCP; 1999. [PubMed: 10624659]
201.
Granton JT, Naughton MT, Benard DC, Liu PP, Goldstein RS, Bradley TD. CPAP improves inspiratory muscle strength in patients with heart failure and central sleep apnea. American Journal of Respiratory & Critical Care Medicine. 1996;153:277–82. [PubMed: 8542129]
202.
Davies RJ, Harrington KJ, Ormerod OJ, Stradling JR. Nasal continuous positive airway pressure in chronic heart failure with sleep-disordered breathing. American Review of Respiratory Disease. 1993;147:630–4. [PubMed: 8442598]
203.
Sin DD, Logan AG, Fitzgerald FS, Liu PP, Bradley TD. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation. 2000;102:61–6. [PubMed: 10880416]
204.
Cowie MR, Fox KF, Wood DA, Metcalfe C, Thompson SG, Coats AJ, et al. Hospitalization of patients with heart failure: a population-based study. European Heart Journal. 2002;23:877–85. [PubMed: 12042009]
205.
Blue L, Lang E, McMurray JJV, Davie AP, McDonagh TA, Murdoch DR, et al. Randomised controlled trial of specialist nurse intervention in heart failure. British Medical Journal. 2001;323:715–8. [PMC free article: PMC56888] [PubMed: 11576977]
206.
Harrison MB, Browne GB, Roberts J, Tugwell P, Gafni A, Graham ID. Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition. Medical Care. 2002;40:271–82. [PubMed: 12021683]
207.
McDonald K, Ledwidge M, Cahill J, Kelly J, Quigley P, Maurer B, et al. Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge. European Journal of Heart Failure. 2001;3:209–15. [PubMed: 11246059]
208.
Parkes J, Shepperd S. Discharge planning from hospital to home. Cochrane Library. 2002
209.
Department of Health. The single assessment process: assessment tools and scales. London: DH; 2002.
210.
Reid LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Therapeutic Drug Monitoring. 1990;12:72–8. [PubMed: 2137650]
211.
Valdes R Jr, Jortani SA, Gheorghiade M. Standards of laboratory practice: cardiac drug monitoring. Clinical Chemistry. 1998;44:1096–109. [PubMed: 9590394]
212.
Howanitz PJ, Steindel SJ. Digoxin therapeutic drug monitoring practices: A College of American Pathologists Q-probes study of 666 institutions and 18,679 toxic levels. Archives of Pathology & Laboratory Medicine. 1993;117:684–90. [PubMed: 8323428]
213.
Canas F, Tanasijevic MJ, Ma’luf N, Bates DW. Evaluating the appropriateness of digoxin level monitoring. Archives of Internal Medicine. 1999;14:363–8. [PubMed: 10030309]
214.
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–30. [PubMed: 10791374]
215.
Diller PM, Smucker DR, David B. Comanagement of patients with congestive heart failure by family physicians and cardiologists: frequency, timing, and patient characteristics. Journal of Family Practice. 1999;48:188–95. [PubMed: 10086761]
216.
Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. New England Journal of Medicine. 1996;334:1441–7. [PubMed: 8618584]
217.
Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA, et al. Randomized, controlled trial of integrated heart failure management: The Auckland Heart Failure Management Study. European Heart Journal. 2002;23:139–46. [PubMed: 11785996]
218.
Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Archives of Internal Medicine. 1999;159:1939–45. [PubMed: 10493325]
219.
Kasper EK, Gerstenblith G, Hefter G, Van A, Brinker JA, Thiemann DR, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. Journal of the American College of Cardiology. 2002;39:471–80. [PubMed: 11823086]
220.
McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. American Journal of Medicine. 2001;110:378–84. [PubMed: 11286953]
221.
Kwan J, Sandercock P. In-hospital care pathways for stroke. Cochrane Database Systematic Review. 2002:CD002924. [PubMed: 12076460]
222.
Improving communication between doctors and patients, A report of the working party. London: Royal College of Physicians of London; 1997. [PubMed: 9192325]
223.
Mullen PD, Green LW, Persinger GS. Clinical trials of patient education for chronic conditions: a comparative meta-analysis of intervention types. Preventive Medicine. 1985;14:753–81. [PubMed: 2418436]
224.
Brown SA. Studies of educational interventions and outcomes in diabetic adults: a meta-analysis revisited. Patient Education & Counseling. 1990;16:189–215. [PubMed: 2149753]
225.
Balas EA, Jaffery F, Kuperman GJ, Austin Boren S, Brown GD, Pinciroli F. Electronic communication with patients: evaluation of distance medicine technology. Journal of the American Medical Association. 1997;278:152–9. [PubMed: 9214532]
226.
Ptacek JT, Eberhardt TL. Breaking bad news. A review of the literature. Journal of the American Medical Association. 1996;276:496–502. [PubMed: 8691562]
227.
Stewart MA. Effective physician-patient communication and health outcomes: a review. Canadian Medical Association Journal. 1995;152:1423–33. [PMC free article: PMC1337906] [PubMed: 7728691]
228.
Department of Health, NHS Executive. Information for health: an information strategy for the modern NHS 1998–2005 a national strategy for local implementation. London: 1998.
229.
Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. British Journal of Cancer. 2001;84:48–51. [PMC free article: PMC2363610] [PubMed: 11139312]
230.
Walden JA, Dracup K, Westlake C, Erickson V, Hamilton MA, Fonarow GC. Educational needs of patients with advanced heart failure and their caregivers. Journal of Heart & Lung Transplantation. 2001;20:766–9. [PubMed: 11448807]
231.
Ni H, Nauman D, Burgess D, Wise K, Crispell K, Hershberger RE. Factors influencing knowledge of and adherence to self-care among patients with heart failure. Archives of Internal Medicine. 1999;159:1613–9. [PubMed: 10421285]
232.
Hinds C, Streater A, Mood D. Functions and preferred methods of receiving information related to radiotherapy. Perceptions of patients with cancer. Cancer Nursing. 1995;18:374–84. [PubMed: 7585492]
233.
Luniewski M, Reigle J, White B. Card sort: an assessment tool for the educational needs of patients with heart failure. American Journal of Critical Care. 1999;8:297–302. [PubMed: 10467466]
234.
Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L. Breaking bad news about cancer: patients’ preferences for communication. Journal of Clinical Oncology. 2001;19:2049–56. [PubMed: 11283138]
235.
Mushlin AI, Mooney C, Grow V, Phelps CE. The value of diagnostic information to patients with suspected multiple sclerosis. Archives of Neurology. 1994;51:67–72. [PubMed: 8274112]
236.
Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist. 2000;5:302–11. [PubMed: 10964998]
237.
Radziewicz R, Baile WF. Communication skills: breaking bad news in the clinical setting. Oncology Nursing Forum. 2001;28:951–3. [PubMed: 11475881]
238.
Girgis A, Sanson-Fisher RW. Breaking bad news: consensus guidelines for medical practitioners. Journal of Clinical Oncology. 1995;13:2449–56. [PubMed: 7666105]
239.
Simpson SH, Farris KB, Johnson JA, Tsuyuki RT. Using focus groups to identify barriers to drug use in patients with congestive heart failure. Pharmacotherapy. 2000;20:823–9. [PubMed: 10907972]
240.
Sandler DA, Mitchell JR, Fellows A, Garner ST. Is an information booklet for patients leaving hospital helpful and useful? British Medical Journal. 1989;298:870–4. [PMC free article: PMC1836154] [PubMed: 2497830]
241.
Serxner S, Miyaji M, Jeffords J. Congestive heart failure disease management study: a patient education intervention. Prevention & Management of Congestive Heart Failure. 1998;4:23–8.
242.
Rogers AE, Addington-Hall JM, Abery AJ, McCoy AS, Bulpitt C, Coats AJ, et al. Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. British Medical Journal. 2000;321:605–7. [PMC free article: PMC27476] [PubMed: 10977838]
243.
Web-based educational effort for CHF patients boosts outcomes while cutting costs. Disease Management Advisor. 2001;7:92–6. [PubMed: 11434241]
244.
Anderson H, Ward C, Eardley A, Gomm SA, Connolly M, Coppinger T, et al. The concerns of patients under palliative care and a heart failure clinic are not being met. Palliative Medicine. 2001;15:279–86. [PubMed: 12054145]
245.
McCarthy M, Hall JA, Ley M. Communication and choice in dying from heart disease. Journal of the Royal Society of Medicine. 1997;90:128–31. [PMC free article: PMC1296175] [PubMed: 9135608]
246.
Cowburn PJ, Cleland GJ, Coats AJ, Komajda M. Risk stratification in chronic heart failure. European Heart Journal. 1989;19:696–710. [PubMed: 9717002]
247.
Smith CE, Curtas S, Robinson JM. Case study of patients helping patients program. Nutrition. 2001;17:175–6. [PubMed: 11240352]
248.
Stewart M, Davidson K, Meade D, Hirth A, Weld-Viscount P. Group support for couples coping with a cardiac condition. Journal of Advanced Nursing. 2001;33:190–9. [PubMed: 11168702]
249.
Hildingh C, Fridlund B. Patient participation in peer suport groups after cardiac event. British Journal of Nursing. 2001;10:1357–63. [PubMed: 11873230]
250.
Friedman MM, Griffin JA. Relationship of physical symptoms and physical functioning to depression in patients with heart failure. Heart & Lung. 2001;30:98–104. [PubMed: 11248712]
251.
Gill D, Hatcher S. Antidepressants for depression in people with medical illness. Cochrane Library. 2001;(2)
252.
McCarthy M, Lay M, Addington-Hall J. Dying from heart disease. Journal of the Royal College of Physicians of London. 1996;30:325–8. [PubMed: 8875378]
253.
Levenson JW, McCarthy EP, Lynn J, Davis RB, Phillips RS. The last six months of life for patients with congestive heart failure. Journal of the American Geriatrics Society. 2000;48:S101–S109. [PubMed: 10809463]
254.
Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. Journal of the American Medical Association. 1989;262:907–13. [PubMed: 2754790]
255.
Lynn J, Teno JM, Phillips RS, Wu AW, Desbiens N, Harrold J, et al. Perceptions by family members of the dying experience of older and seriously ill patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Annals of Internal Medicine. 1997;126:97–106. [PubMed: 9005760]
256.
Koenig HG. Depression in hospitalized older patients with congestive heart failure. General Hospital Psychiatry. 1998;20:29–43. [PubMed: 9506252]
257.
Thorns AR, Gibbs LM, Gibbs JS. Management of severe heart failure by specialist palliative care. Heart. 2001;85:93. [PMC free article: PMC1729585] [PubMed: 11119475]
258.
Teno JM, Weitzen S, Fennell ML, Mor V. Dying trajectory in the last year of life: does cancer trajectory fit other diseases? Journal of Palliative Medicine. 2001;4:457–64. [PubMed: 11798477]
259.
Hearn J, Higginson IJ. Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Palliative Medicine. 1998;12:317–32. [PubMed: 9924595]
260.
Higginson IJ, Finlay I, Goodwin DM, Cook AM, Hood K, Edwards AG, et al. Do hospital-based palliative teams improve care for patients or families at the end of life? Journal of Pain and Symptom Management. 2002;23:96–106. [PubMed: 11844629]
261.
Diagnosis and treatment of heart failure due to left ventricular systolic dysfunction. Edinburgh; Scottish Intercollegiate Guidelines Network: 1999.
262.
Management of diabetes A national clinical guideline. Edinburgh; SIGN Executive: 2001.
263.
National Institute of Clinical Excellence. Management of type 2 diabetes, renal disease – prevention and early management. London: NICE; 2002.
264.
National Institute of Clinical Excellence. Management of type 2 diabetes, retinopathy – early management and screening. London: NICE; 2002.
265.
National Institute of Clinical Excellence guideline on prophylaxis for patients who have experienced a myocardial infarction : Drug treatment, cardiac rehabilitation and dietary manipulation. London: NICE; 2002.
266.
Myocardial infarction – detailed guideline. London: NICE; 2002.
267.
Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. Journal of Human Hypertension. 1999;13:569–92. [PubMed: 10482967]
268.
Brooks N. Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. Heart. 2001;85:133–42. [PMC free article: PMC1729608] [PubMed: 11156660]
269.
Hummel S, Piercy J, Wright R, Davie A, Bagust A, McMurray J. An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom. Pharmacoeconomics. 1997;12:182–92. [PubMed: 10169670]
270.
McMurray JJ, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. European Heart Journal. 1997;18:1411–5. [PubMed: 9458446]
271.
Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, et al. Cost-effectiveness of captopril therapy after myocardial infarction. Journal of the American College of Cardiology. 1995;26:914–9. [PubMed: 7560617]
272.
Walsh JT, Gray D, Keating NA, Cowley AJ, Hampton JR. ACE for whom? Implications for clinical practice of post-infarct trials. British Heart Journal. 1995;73:470–4. [PMC free article: PMC483866] [PubMed: 7786664]
273.
Hobbs RE. Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure? Cleveland Clinic Journal of Medicine. 1998;65:539–42. [PubMed: 9830787]
274.
Hillis GS, Trent RJ, Winton P. Angiotensin-converting-enzyme inhibitors in the management of of cardiac failure: are we ignoring the evidence? Quarterly Journal of Medicine. 1995;89:145–50. [PubMed: 8729556]
275.
Doyle JC, Mottram DR, Stubbs H. Prescribing of ACE inhibitors for cardiovascular disorders in general practice. Journal of Clinical Pharmacy and Therapeutics. 1998;23:133–6. [PubMed: 9786099]
276.
Hobbs FDR, Jones MI, Allan TF, Wilson S, Tobias R. European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF) European Heart Journal. 2000;21:1877–87. [PubMed: 11052861]
277.
Vince JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. Journal of the American Geriatrics Society. 1990;38:1290–5. [PubMed: 2254567]
278.
Sculpher MJ, Poole L, Cleland J, Drummond M, Armstrong PW, Horowitz JD, et al. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. European Journal of Heart Failure. 2000;2:447–54. [PubMed: 11113723]
279.
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Journal of the American Medical Association. 1995;273:1450–6. [PubMed: 7654275]
280.
Cornell S, Calvert NW, Channer KS, Singleton CD. Angiotensin-converting anzyme (ACE) inhibitors in heart failure: reducing mortality and costs to the NHS. 98(05). Trent Institute for Health Services Research; 1998.
281.
North of England Evidence Based Guideline Development Project. Prophylaxis for patients who have experienced a MI: drug treatment, Cardiac rehabiliation and dietary manipulation. Centre for Health Services Research; Newcastle: 2001.
282.
North of England Evidence Based Guideline Development Project. Evidence based clinical practice guideline, ACE inhibitors in the primary care management of adults with symptomatic heart failure. Newcastle: Centre for Health Services Research, University of Newcastle; 1997.
283.
Schneeweiss S. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. New England Journal of Medicine. 2002;346:822–9. [PubMed: 11893794]
284.
McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics. 1996;9:188–97. [PubMed: 10160096]
285.
McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. British Journal of Medical Economics. 1993;6:99–110.
286.
Glick H, Cook J, Kinosian B. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the SOLVD treatment trial. Journal of Cardiac Failure. 1995;1:371–80. [PubMed: 12836712]
287.
O’Keeffe S, Harvey G, Lye M. Use of angiotensin-converting enzyme, inhibitors in elderly patients with heart failure. Age and Ageing. 1998;27:297–301.
288.
Missouris CG, MacGregor GA. The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice. Postgraduate Medical Journal. 1997;73:409–11. [PMC free article: PMC2431408] [PubMed: 9338025]
289.
Mair FS, Carowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. British Journal of General Practice. 1996;46:77–9. [PMC free article: PMC1239534] [PubMed: 8855012]
290.
Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. British Heart Journal. 1994;71:584–7. [PMC free article: PMC1025459] [PubMed: 8043344]
291.
Sanderson S. Ace inhibitors in the treatment of chronic heart failure: effective and cost effective. Bandolier. 1994;1
292.
Varney S. A cost-effectiveness analysis of bisoprolol for heart failure. European Journal of Heart Failure. 2001;3:365–71. [PubMed: 11378009]
293.
Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. American Journal of Cardiology. 1999;83:890–6. [PubMed: 10190405]
294.
Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clinical Therapeutics. 1999;21:854–66. [PubMed: 10397380]
295.
Channer K, Robertson E. Echocardiography or cardiac catheterisation – a comparison of risks, benefits and costs. Health Trends. 1991;23:141–4. [PubMed: 10117733]
296.
Goldstein DJ, Mehmet C, Rose EA. Implantable left ventricular assist devices. New England Journal of Medicine. 1998;339:1522–33. [PubMed: 9819452]
297.
Robert G, Caine N, Sharples LD, Large SR, Wallwork J. Assessing low volume, high cost, potentially life saving surgical interventions: how and when? Left ventricular assist devices (LVADs) as a case study. Journal of Evaluation in Clinical Practice. 1999;5:387. [PubMed: 10579702]
298.
Frazier OH, Rose EA, McCarthy PM. Improved mortality and rehabilitation of transplant candidates treated with long-term implantable left ventricular assist system. Annals of Surgery. 1995;222:327–38. [PMC free article: PMC1234813] [PubMed: 7677462]
299.
Morales DL, Argenziano M, Oz MC. Outpatient left ventricular assist device support: a safe and economical therapeutic option for heart failure. Progress in Cardiovascular Diseases. 2000;43:55–66. [PubMed: 10935558]
300.
Buxton MJ, Acheson R, Caine N, Gibson S, O’Brien B. Costs and benefits of the heart transplant programmes at Harefield and Papworth Hospitals, Department of Health and Social Security. London: Her Majesty’s Stationery Office; 1985.
301.
Sharples LD, Briggs A, Caine N, McKenna M, Buxton MJ. A model for anayzing the cost of main clinical events after cardiac transplantation. Transplantation. 1996;62:615–21. [PubMed: 8830825]
302.
Dew MA, Switzer GE, Goycoolea M. Does transplantation produce quality of life benefits: a quantitative analysis of the literature. Transplantation. 1997;64:1261–73. [PubMed: 9371666]
303.
Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999;99:1173–82. [PubMed: 10069785]
304.
Schocken D, Arrieta M, Leaverton P. Prevalence and mortality rate of congestive heart failure in the United States. Journal of the American College of Cardiology. 1992;20:301–6. [PubMed: 1634664]
305.
Capomolla S. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. Journal of the American College of Cardiology. 2002;40:1259–66. [PubMed: 12383573]
306.
Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. British Medical Journal. 1996;312:222. [PMC free article: PMC2350031] [PubMed: 8563589]
307.
Hart W, Rhodes G, McMurray J. The cost effectiveness of enalapril in the treatment of chronic heart failure. British Journal of Medical Economics. 1993;6:91–8.
308.
Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic review and meta-analysis. American Journal of Medicine. 1990;88:279–86. [PubMed: 2178412]
309.
Martinez C, Ball SG. Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction. British Journal of Clinical Practice. 1995;49:26–32.
310.
Butler JR, Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust NZ J Med. 1996;26:89–95. [PubMed: 8775534]
311.
van Hout BA, Wielink G, Bonsel GJ, Rutten FF. Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model. Pharmacoeconomics. 1993;3:387–97. [PubMed: 10146889]
312.
Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med. 1994;154:1143–9. [PubMed: 8185426]
313.
Scott WG, Scott HM. Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction. Pharmacoeconomics. 1996;9:156–67. [PubMed: 10160094]
314.
Erhardt L, Ball S, Andersson F, Bergentoft P, Martinez C. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. Pharmacoeconomics. 1997;12:256–66. [PubMed: 10170450]
315.
Schadlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics. 1998;14:653–69. [PubMed: 10346417]
316.
Andersson F, Cline C, Ryden-Bergsten T, Erhardt L. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing. Pharmacoeconomics. 1999;15:535–50. [PubMed: 10538327]
317.
Hart W, Rhodes G, McMurray J. The cost effectiveness of enalapril in the treatment of chronic heart failure. British Journal of Medical Economics. 1993;6:91–8.
318.
McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–33. [PubMed: 9310600]
319.
McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(Suppl P):9–16. [PubMed: 9886707]
320.
Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract. 1996;46:77–9. [PMC free article: PMC1239534] [PubMed: 8855012]
321.
Clark AL, Coats AJ. New evidence for improved survival in chronic heart failure. Clin Cardiol. 1994;17:55–8. [PubMed: 8162626]
322.
Hobbs FD. Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br J Gen Pract. 2000;50:735–42. [PMC free article: PMC1313804] [PubMed: 11050792]
323.
Mason J, Young P, Freemantle N, Hobbs R. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. BMJ. 2000;321:1113–6. [PMC free article: PMC27519] [PubMed: 11061732]
324.
Netten A, Dennett J, et al. Unit costs of health and social care 1997. PSSRU, University of Kent; 1997.
325.
Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. PSSRU, University of Kent; 2001.
326.
Kalra PA, Kumwenda M, MacDowall P, Roland MO. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ. 1999;318:234–7. [PMC free article: PMC27706] [PubMed: 9915733]
327.
Schadlich PK, Paschen B, Brecht JG. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. Pharmacoeconomics. 1998;13:147–55. [PubMed: 10176149]
328.
Malek M, Cunningham-Davis J, Malek L, Paschen B, Tavakoli M, Zabihollah M, et al. A cost minimisation analysis of cardiac failure treatment in the UK using CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Int J Clin Pract. 1999;53:19–23. [PubMed: 10344061]
329.
Levy P, Lechat P, Leizorovicz A, Levy E. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther. 1998;12:301–5. [PubMed: 9784910]
330.
Mosher BA, Abrahamson D. Cost analysis of loop diuretics in heart failure. Congestive Heart Failure. 1995;6:26–31.
331.
Heaton AH, Bryant J, Berman BN, Trotter JP. Pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure. Med Interface. 1996;9:101–7. [PubMed: 10153789]
332.
Spannheimer A, Goertz A, Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract. 1998;52:467–71. [PubMed: 10622087]
333.
Stroupe KT, Forthofer MM, Brater DC, Murray MD. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17:429–40. [PubMed: 10977385]
334.
Christopher F, Clegg A. Left ventricular assist devices (LVADs) for end stage heart failure, Development and Evaluation Committee Report No. 103. Southampton: The Wessex Institute for Health Research and Development; 2001.
335.
Taggart DP, Westaby S. Surgical management of heart failure. BMJ. 1997;314:453–4. [PMC free article: PMC2125997] [PubMed: 9056784]
336.
McGregor M. Implantable ventricular assist devices: is it time to introduce them in Canada? Canadian Journal of Cardiology. 2000;16:629–40. [PubMed: 10833542]
337.
Moskowitz AJ, Weinberg A, Oz MC, Williams DL. Quality of life with an implanted left ventricular assist device. Annals of Thoracic Surgery. 1997;64:1764–9. [PubMed: 9436569]
338.
National Horizon Scanning Centre. New and Emerging Technolgy Briefing. National Horizon Scanning Centre, University of Birmingham; 2001. Ventricular pacing and resynchronisation for heart failure.
339.
Georgiou D, Chen Y, Appadoo S, Belardinelli R, Greene R, Parides MK, et al. Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. American Journal of Cardiology. 1915;87:984–8A4. [PubMed: 11305991]
340.
Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421–8. [PubMed: 10213345]
341.
Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ. 2000;320:985–6. [PMC free article: PMC27340] [PubMed: 10753153]
342.
Campbell NC, Cowie MR, Hannaford PC, Ritchie LD, Murchie P. Prevalence and detection of left ventricular dysfunction in diabetic patients in primary care. Department of General Practice and Primary Care, University of Aberdeen. Chief Scientist Office; 2001.
343.
McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13. [PubMed: 9433422]
344.
Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. Journal of Hypertension. 2000;18:1121–8. [PubMed: 10954005]
345.
Rihal CS, Davis KB, Kennedy WJ, Gersh BJ. The utility of clinical, electrocardiographic and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol. 1995;75:220–3. [PubMed: 7832126]
346.
Mosterd A, de Bruijne MC, Hoes AW, Deckers JW, Hofman A, Grobbee DE. Usefulness of echocardiography in detecting left ventricular dysfunction in population-based studies (The Rotterdam Study) Am J Cardiol. 1997;79:103–4. [PubMed: 9024752]
347.
Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. BMJ. 2000;320:220–4. [PMC free article: PMC27270] [PubMed: 10642232]
Copyright © 2003, Royal College of Physicians of London.
Bookshelf ID: NBK65610

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.7M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...